Navigation Links
Cardiac Science Completes Deployment of AEDs With Los Angeles County Fire Department

BOTHELL, Wash., Jan. 18 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced that the Los Angeles County Fire Department equipped its first responder units with 425 Powerheart(R) G3 and G3 Pro(R) automated external defibrillators (AEDs).


"Like first responders everywhere, LA County Fire is a critical link in the survival chain, delivering life-saving trauma interventions immediately upon its arrival at an accident scene, or when responding to a sudden cardiac arrest," said Battalion Chief Ed Gandara, Emergency Medical Services Section. "A shock to the heart from an external defibrillator within a few minutes of a sudden cardiac arrest is absolutely critical. We want to equip our paramedics with the right equipment to increase the likelihood of resuscitating a victim." After thorough review, LA County Fire chose to outfit its units with Powerheart AEDs from Cardiac Science.

The Powerheart AED G3 and G3 Pro defibrillators are designed to be the most advanced and reliable defibrillation products on the market today. They meet and exceed tough clinical and environmental standards for professional fire and emergency medical services. Features on the G3 Pro include the industry's first ECG color display in an AED, manual override, three-lead monitoring and multiple rescue capability. These products also provide the ability to download rescue data to LA County Fire's data management system directly from the device, simplifying medical review and reporting of cardiac events.

"LA County required data connectivity from their AEDs," said Tony Titus, vice president of marketing. "Since our Quinton(R) and Burdick(R) cardiac monitoring products connect to many Health Information and Electronic Medical Record systems using our HeartCentrix(R) technology, we extended the application to our Powerheart AEDs to meet their specific requirements."

About Los Angeles County Fire Department

LA County Fire provides fire and EMS services to more than four million residents over 2,300 square miles in Los Angeles County, including 58 cities and towns. LA County Fire professionals include more than 2800 safety personnel, in addition to more than 700 lifeguards and numerous other support personnel. In 2006, LA County Fire first responders treated nearly 200,000 victims.

About the Powerheart AED by Cardiac Science

Having won more than 80 Powerheart patents, Cardiac Science engineers build AEDs with some of the most technologically advanced, easiest-to-use features available in AEDs today. Hospitals, police and fire departments use Powerheart AEDs to meet or exceed their demanding clinical needs. Major corporations, public agencies, airlines and airports, arenas, schools, hotels, casinos and consumers prefer Powerheart for its intuitive ease of use.

About Cardiac Science Corporation

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), Powerheart(R), Quinton(R), and HeartCentrix(R) brands, is headquartered in Bothell, Washington. The company, with customers in more than 100 countries worldwide, has operations in the United States (California and Wisconsin), Europe, and Asia. For information, call 425-402-2000 or visit

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, those which infer that Cardiac Science Corporation's future revenue and profits may grow as a result of sales of defibrillation products. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future performance. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2006. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Cardiac Science Corporation Contact:

Mike Matysik

Senior Vice President and CFO


Investor Contact:

EVC Group, Inc.

Douglas Sherk/Jenifer Kirtland


Media Contact:

EVC Group, Inc.

Steve DiMattia


SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association
3. Family History Has Strong Effect on Cardiac Risk
4. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
5. Cardiac Science to Present at the UBS Global Life Sciences Conference
6. Cardiac Science Applauds Mass AED Training of Pittsburgh Educators
7. Guidelines help patients reduce risk of cardiac event before surgery
8. Cardiac Science Named to Deloittes Technology Fast 50 for Washington State
9. Cleveland Clinic and The Larry King Cardiac Foundation Partner to Provide Heart Surgery to Those in Need
10. Cardiac Science Releases New Cardiac Rehabilitation System
11. Cardiac Artery Trouble Boosts Family Heart Risk
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: